Código QR (código de barras bidimensional)

Clinical efficacy of casirivimab and imdevimab in preventing COVID-19 in the Omicron BA.5 subvariant epidemic: a retrospective study

Abstract Background The neutralizing monoclonal antibody combination of casirivimab and imdevimab (CAS + IMD) is the only therapy approved for preventing coronavirus disease 2019 (COVID-19) following exposure to severe acute respiratory syndrome coronavirus 2. However, the efficacy of CAS + IMD agai...

ver descrição completa

Na minha lista:
Principais autores: Mariko Ohtani, Takuya Yokoo, Taito Miyazaki, Hiroshi Yasuda, Eriko Nishikawa, Manabu Tomida, Mayumi Tsukada, Emi Sato, Shinobu Hirayama, Hinako Murakami, Sadako Yoshizawa, Takahiro Matsumoto, Kazuhiro Tateda
Formato: Artigo
Idioma:Inglês
Publicado em: BMC 2025-10-01
coleção:Journal of Pharmaceutical Health Care and Sciences
Assuntos:
COVID-19
Casirivimab
Imdevimab
Post-exposure prophylaxis
Omicron
Acesso em linha:https://doi.org/10.1186/s40780-025-00501-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados